"RANK Ligand" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.
| Descriptor ID |
D053245
|
| MeSH Number(s) |
D12.644.276.374.750.562 D12.776.467.374.750.562 D23.529.374.750.562
|
| Concept/Terms |
RANK Ligand- RANK Ligand
- OPGL Protein
- Osteoclast Differentiation Factor
- Differentiation Factor, Osteoclast
- Osteoprotegerin Ligand
- Receptor Activator of Nuclear Factor-kappa B Ligand
- Receptor Activator of Nuclear Factor kappa B Ligand
- Receptor Activator of Nuclear Factor-kappaB Ligand
- Receptor Activator of Nuclear Factor kappaB Ligand
- Tumor Necrosis Factor Ligand Superfamily Member 11
- TNF Superfamily, Member 11
- RANKL Protein
- Tumor Necrosis Factor-Related Activation-Induced Cytokine
- Tumor Necrosis Factor Related Activation Induced Cytokine
- CD254 Antigen
- Antigen, CD254
- TRANCE Protein
|
Below are MeSH descriptors whose meaning is more general than "RANK Ligand".
Below are MeSH descriptors whose meaning is more specific than "RANK Ligand".
This graph shows the total number of publications written about "RANK Ligand" by people in this website by year, and whether "RANK Ligand" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 3 | 5 |
| 2010 | 2 | 1 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 3 | 2 | 5 |
| 2014 | 1 | 3 | 4 |
| 2016 | 3 | 1 | 4 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "RANK Ligand" by people in Profiles.
-
Osteoclast-Mediated Cell Therapy as an Attempt to Treat Elastin Specific Vascular Calcification. Molecules. 2021 Jun 15; 26(12).
-
Characterization of metabolic responses, genetic variations, and microsatellite instability in ammonia-stressed CHO cells grown in fed-batch cultures. BMC Biotechnol. 2021 01 08; 21(1):4.
-
Kynurenine Promotes RANKL-Induced Osteoclastogenesis In Vitro by Activating the Aryl Hydrocarbon Receptor Pathway. Int J Mol Sci. 2020 Oct 26; 21(21).
-
Selective serotonin reuptake inhibitors (SSRI) affect murine bone lineage cells. Life Sci. 2020 Aug 15; 255:117827.
-
RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma. J Cell Physiol. 2020 02; 235(2):1663-1673.
-
Sphingosine-1-Phosphate Receptor 2 Controls Podosome Components Induced by RANKL Affecting Osteoclastogenesis and Bone Resorption. Cells. 2019 01 01; 8(1).
-
Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells. J Cell Physiol. 2018 08; 233(8):6125-6134.
-
Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5. Sci Rep. 2016 08 23; 6:32001.
-
Microgravity Induction of TRAIL Expression in Preosteoclast Cells Enhances Osteoclast Differentiation. Sci Rep. 2016 05 04; 6:25143.
-
Failure to Target RANKL Signaling Through p38-MAPK Results in Defective Osteoclastogenesis in the Microphthalmia Cloudy-Eyed Mutant. J Cell Physiol. 2016 Mar; 231(3):630-40.